FOR THE EVADIAC SENSOR STUDY

OBJECTIVEdThe benefits of real-time continuous glucose monitoring (CGM) have been dem-onstrated in patients with type 1 diabetes. Our aimwas to compare the effect of twomodes of use of CGM, patient led or physician driven, for 1 year in subjects with poorly controlled type 1 diabetes. RESEARCH DESIGN AND METHODSdPatients with type 1 diabetes aged 8–60 years with HbA1c $8 % were randomly assigned to three groups (1:1:1). Outcomes for glucose control were assessed at 1 year for two modes of CGM (group 1: patient led; group 2: physician driven) versus conventional self-monitoring of blood glucose (group 3: control). RESULTSdA total of 257 subjects with type 1 diabetes underwent screening. Of these, 197 were randomized, with 178 patients completing the study (age: 36 6 14 years; HbA1c: 8.9 6 0.9%). HbA1c improved similarly in both CGM groups and was reduced compared with the control group (group 1 vs. group 3:20.52%, P = 0.0006; group 2 vs. group 3:20.47%, P = 0.0008; groups 1 + 2 vs. group 3:20.50%, P, 0.0001). The incidence of hypoglycemia was similar in the three groups. Patient SF-36 questionnaire physical health score improved in both experimental CGM groups (P = 0.004). Sensor consumption was 34 % lower in group 2 than in group 1 (median [Q1–Q3] con-sumption: group 1: 3.42/month [2.20–3.91] vs. group 2: 2.25/month [1.27–2.99], P = 0.001)